Attention: This platform is in beta mode. Expect some changes and adjustments.

AI Market Mood: Stock Dashboard

TNDM


Fundamental

Company: Tandem Diabetes Care Inc
Sector: Healthcare
Industry: Medical Devices
Country: USA
Exchange: NASD
Index: RUT
P/E: -
EPS (ttm): -3.05
Insider Own: 1.03%
Shs Outstand: 67.77M
Perf Week: -1.15%
Market Cap: 1.28B
Forward P/E: -
EPS next Y: -0.92
Insider Trans: 0.00%
Shs Float: 67.10M
Perf Month: -9.20%
Enterprise Value: 1.42B
PEG: -
EPS next Q: -0.09
Inst Own: 112.87%
Short Float: 13.31%
Perf Quarter: 4.93%
Income: -203.37M
P/S: 1.28
EPS this Y: -45.09%
Inst Trans: -7.14%
Short Ratio: 5.53
Perf Half Y: 77.77%
Sales: 1.01B
P/B: 9.66
EPS next Y Percentage: 56.65%
ROA: -22.20%
Short Interest: 8.93M
Perf YTD: -13.79%
Book/sh: 1.96
P/C: 4.03
EPS next 5Y: 44.82%
ROE: -109.73%
52W High: 35.12 -46.04%
Perf Year: -41.89%
Cash/sh: 4.71
P/FCF: -
EPS past 3/5Y: - -28.23%
ROIC: -36.26%
52W Low: 9.98 89.88%
Perf 3Y: -54.52%
Dividend Est.: -
EV/EBITDA: -
Sales past 3/5Y: 10.19% 21.01%
Gross Margin: 53.23%
Volatility W: 6.29%
Volatility M: 5.77%
Perf 5Y: -81.84%
Dividend TTM: -
EV/Sales: 1.41
EPS Y/Y TTM: -57.03%
Oper. Margin: -9.75%
ATR (14): 1.12
Perf 10Y: -72.05%
Dividend Ex-Date: -
Quick Ratio: 1.90
Sales Y/Y TTM: 17.87%
Profit Margin: -20.20%
RSI (14): 41.20
Recom: 2.40
Dividend Gr. 3/5Y: - -
Current Ratio: 2.44
EPS Q/Q: 11.84%
SMA20: -3.65%
Beta: 1.69
Target Price: 25.55
Payout: -
Debt/Eq: 3.38
Sales Q/Q: 2.17%
SMA50: -9.57%
Rel Volume: 0.47
Prev Close: 18.69
Employees: 2650
LT Debt/Eq: 3.22
Earnings: Feb 19 AMC
SMA200: 7.77%
Avg Volume: 1.62M
Price: 18.95
IPO: Nov 14, 2013
Option/Short: Yes / Yes
EPS/Sales Surpr.: 4.98% 5.72%
Trades:
Volume: 753,129
Change: 1.39%

Technical:


Latest News:

Abbott to integrate CGM with Medtronic's insulin delivery devices - Seeking Alpha neutral
ABT MDT NVO PODD TNDM DXCM

Summary: Abbott partners with Medtronic for integrating its CGM system with AID and smart insulin pen systems, with financial terms undisclosed.

Full article
2024-08-07T14:07:23Z
Wells Fargo Upgrades Tandem Diabetes Care (TNDM) - Nasdaq somewhat bullish
TNDM

Summary: Tandem Diabetes Care (TNDM) had its outlook upgraded from Equal-Weight to Overweight by Wells Fargo. The average price target suggests a 1.09% downside. Funds reporting positions in TNDM increased by 35, and there is a bullish outlook indicated by a put/call ratio of 0.55.

Full article
2024-04-30T13:53:52Z